Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06351345 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

129 Xenon Imaging in Patients Treated With Sotatercept

Study acronym: Sox-PH
StatusRecruiting
PhasePhase 2
Started2025-10-27
View on ClinicalTrials.gov ↗

Amendment history

2026-02-23
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v10
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-08-01→2029-02-04
Completion date2026-08-01→2030-02-04
Start dateestimated 2025-11-01→confirmed 2025-10-27
Study sitesdetails revised at 1 of 1 site
2025-10-17
Study Status, Contacts/Locations v9
Re-verified, no change to tracked fields
2025-10-13
Study Status v8
Start date2025-09-01→2025-11-01
2025-07-18
Study Status v7
Start date2025-07-01→2025-09-01
2025-05-15
Study Status v6
Start date2025-05-01→2025-07-01
Show 5 earlier versions
2025-03-18
Study Identification, Study Status v5
Primary completion date2025-08-01→2026-08-01
Completion date2025-08-01→2026-08-01
Start date2025-03-01→2025-05-01
Study titlerevised
129 Xenon Imaging in Patients Treated withWith Sotatercept
2025-01-16
Study Status v4
Start date2024-12-01→2025-03-01
2024-11-14
Study Identification, Study Status, Oversight v3
Start date2024-09-01→2024-12-01
Study titlerevised
129 Xenon Imaging in Patients Treated Withwith Sotatercept
2024-07-13
Study Status, Study Description, Outcome Measures v2
Study description-2 characters
[...] e. At baseline (prior to the treatment with sotatercept), 3, 6 and 12 months of follow-up, the research team will perform [...]
2024-07-10
Study Status v1
Start date2024-06-01→2024-09-01
2024-04-02
Original filing
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
Trial Details
NCT Number NCT06351345
Lead Sponsor Bastiaan Driehuys
Collaborators: Merck Sharp & Dohme LLC
Conditions Pulmonary Hypertension, Pulmonary Arterial Hypertension
Enrollment 14 participants
Start Date 2025-10-27
Primary Completion 2029-02-04 (estimated)
Study Completion 2030-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-24